Paper Details

  1. Home
  2. Paper Details

Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study.

Author: LeeJacob, NaSun Hee, ParkJin Ju, SeoYu Bin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A study of 414 patients with COVID-19 found that the prescription rate for nirmatrelvir/ritonavir was low, with most non-prescriptions being due to patient refusal. Symptom resolution was faster in the prescription group, and no life-threatening side effects were reported.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Nirmatrelvir/ritonavir was Korea's first oral antiviral agent to treat coronavirus disease 2019 (COVID-19). We analyzed the nirmatrelvir/ritonavir prescription rate and treatment outcomes in treatment-eligible patients with COVID-19 receiving home-based care. MATERIALS AND METHODS: We r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840968/

データ提供：米国国立医学図書館（NLM）

Nirmatrelvir/Ritonavir: A New Weapon in the Fight Against COVID-19?

Dr. Camel here, venturing into the ever-evolving landscape of COVID-19 research. This study explores the use of nirmatrelvir/ritonavir, a promising oral antiviral treatment, in patients with COVID-19 who are receiving home-based care. Researchers analyzed data from a single center in Korea, examining the prescription rate of nirmatrelvir/ritonavir, the reasons for non-prescription, and patient outcomes.

Navigating the Desert of COVID-19 Treatment

The study found that the prescription rate of nirmatrelvir/ritonavir was relatively low, with a significant number of patients refusing treatment. However, those who received the medication experienced faster symptom resolution and no life-threatening side effects.

Finding Relief in the Desert

This research highlights the importance of patient education and informed decision-making regarding COVID-19 treatment options. It emphasizes the need to provide accurate information about the safety and effectiveness of antiviral medications to empower patients to make informed choices about their care.

Dr.Camel's Conclusion

This study provides valuable insights into the use of nirmatrelvir/ritonavir for COVID-19 treatment. While further research is needed to optimize its use, it offers a promising potential tool for managing COVID-19 and improving patient outcomes. This study underscores the importance of ongoing research and development to combat the challenges of emerging infectious diseases.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-01-31
Further Info :

Pubmed ID

36450290

DOI: Digital Object Identifier

PMC9840968

Related Literature

Article Analysis
・Side Effects of nirmatrelvir and ritonavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.